Figure 5

Jul 31, 2014

20 likes | 194 Views

Figure 1. Figure 4. Figure 3. Figure 5 Potential Growth from Establishing a MUHC PCP Relationship with Patients without a Designated PCP. Figure 2.

Share Presentation

Embed Code

Link

figure
potential growth
muhc pcp relationship

liza

Download Presentation

Figure 5

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Figure 1 Figure 4 Figure 3 Figure 5 Potential Growth from Establishing a MUHC PCP Relationship with Patients without a Designated PCP. Figure 2

Figure 5-60

Figure 5-60. Page 122. EcoRI. Tetracycline Resistance. Ampicillin Resistance. PstI. HindIII. +. +. +. +. +. Origin of Replication. A plasmid. Figure 5-43 The pUC18 cloning vector. Page 106. Figure 5-46 Construction of a recombinant DNA molecule. Page 108.

846 views • 54 slides

Figure 5-39

Figure 5-39. Analog to Analog Modulation.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-40.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-41. Amplitude Modulation.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-42.

409 views • 8 slides

Supplementary figure 5

A. GBT-B1 (^Gal4-VP16). B. GBT-B2 (^Gal4-FF). Supplementary Figure 1. D. Supplementary figure 5.

139 views • 1 slides

Supplementary Figure 5

Supplementary Figure 5.

66 views • 1 slides

Figure 5-22

Figure 5-22. Digital to Analog Encoding. 3 Characteristics of a sine wave Amplitude Frequency Phase 3 Mechanisms for Modulating Digital Data into Analog Signal ASK FSK PSK. Figure 5-23. Bit Rate and Baud Rate. Bit rate number of bits transmitted during 1 second Baud rate

1.16k views • 32 slides

Supplemental Figure 5

Supplemental Figure 5. A. MTLn3 GFP-CXCL12. MTLn3 GFP-pQCXIP. C. B. ***. CXCR4. IgG. % of max. BMM Chemotaxis to CXCL12. % of max. CXCR4-PE. CXCR4-PE. IgG. CXCR4. B.

126 views • 1 slides

Supplementary Figure 5.

Supplementary Figure 5. A. i.c.v. Ghrelin. AVV injection in VTA. FI. B. C. 2h. D.

86 views • 1 slides

Supplemental Figure 5

Trastuzumab-treated. Control-treated. A. MDA-MB-453. 14.2%. 10.7%. DEAB-inhibited. DEAB-inhibited. B. JIMT-1. 5.2%. 5.4%. DEAB-inhibited. DEAB-inhibited. C. Sum159-HER2. 7.1%. 36%. DEAB-inhibited. DEAB-inhibited. Trastuzumab-treated. Control-treated. D. Supplemental Figure 5.

140 views • 1 slides

Figure 5

2° ab alone. GPBAR1+ LPMC. Control TNBS + vehicle TNBS + Ciprofloxacin. A B E. Control TNBS TNBS

155 views • 1 slides

Supplementary Figure 5

Supplementary Figure 5. A. B. MITOCHONDRIA. TOTAL. WT. S46A. WT. S46A. p53. RITA. –. +. +. –. WB: p53. % of apoptotic cells. α-amanitin. –. +. –. +. WB: VDAC. WB: HIPK2. WB: PCNA. WB: p53pS46. NT. RITA. WB: p53. WB: Actin. C. D. pLPC. Pin1-HA. MITOCHONDRIA. TOTAL.

131 views • 1 slides

Supplemental Figure 5

Supplemental Figure 5.

82 views • 1 slides

Figure 5

Figure 5. Anna C. Seale. (2013) 74 , 00-00. doi:10.1038/pr.2013.207.

152 views • 1 slides

Suppl Figure 5

Suppl Figure 5. WT ctl1. WT ctl1. conditional defect. NO 3 - , Cl - , sucrose Hermans et al . (2010). Low, moderate NO 3 -. High NO 3 -. Endogenous content/production ABA ↓ C K ↑ C 2 H 4 ↑↑ Exogenous supply ABA induces the arm phenotype

155 views • 1 slides

Figure 5-16

Figure 5-16. Analog to Digital Encoding.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-17. PAM.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-18. Quantized PAM Signal.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-19.

456 views • 27 slides

Supplemental Figure 5

Supplemental Figure 5. p <0.05. p =0.05. a. b. p <0.05. p <0.05. p <0.05. p <0.05. c. Muscle. d. Liver. + - + - UCP3. p <0.01. UCP3. SDH. p <0.05.

91 views • 1 slides

Supplementary Figure 5

Supplementary Figure 5. A. 6h 12h 18h 24h. Rab 3B myosin heavy chain 7 putative cold shock domain protein A myosin heavy chain 4 myosin heavy chain 3 actinin alpha 2 E-cadherin. 0.2. B. 1.0. CONTROL 24 h. BaP 24 h. 5.0. (a). (b).

104 views • 1 slides

Supplement Figure 5

(XB130). (XB130). Supplement Figure 5. A. B. C.

96 views • 2 slides

Supplementary Figure 5

A. C. B. Supplementary Figure 5.

67 views • 1 slides

Figure 5

Figure 5.

86 views • 1 slides

Figure 5-15

Figure 5-15. Analog to Digital Encoding.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-16. PAM.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-17. Quantized PAM Signal.  The McGraw-Hill Companies, Inc., 1998. WCB/McGraw-Hill. Figure 5-18.

354 views • 27 slides

Supplementary Figure 5

Supplementary Figure 5. a. T80. HEY. ATG5 shRNA H2-1 + FAC. ATG5 shRNA H2-2 + FAC. ATG5 shRNA H2-1 + FAC. ATG5 shRNA H2-2 + FAC. ATG5 shRNA H2-1. ATG5 shRNA H2-2. Control-1 + FAC. Control-2 + FAC. ATG5 shRNA H2-1. ATG5 shRNA H2-2. Control-1 + FAC. Control-2 + FAC. Control-1.

108 views • 1 slides

Figure 5

b. a. Figure 5. c.

87 views • 1 slides

More Related